Brief: InMed Pharmaceuticals Announces Update On Phase 2 Clinical Trial Investigating Inm-755 Cannabinol Cream For Epidermolysis Bullosa

InMed Pharmaceuticals

25/07/2022 13:58

July 25 (Reuters) - InMed Pharmaceuticals Inc  INM.O :
    * INMED ANNOUNCES UPDATE ON PHASE 2 CLINICAL TRIAL
INVESTIGATING
INM-755 CANNABINOL CREAM FOR EPIDERMOLYSIS BULLOSA
    * INMED PHARMACEUTICALS INC - PHASE 2 CLINICAL TRIAL
RECENTLY
EXPANDED TO INCLUDE ADOLESCENTS FOLLOWING INDEPENDENT REVIEW OF
EARLY SAFETY DATA
    * INMED PHARMACEUTICALS INC - FIRST ADOLESCENT PATIENT WITH
EB
ENROLLED INTO CLINICAL TRIAL AND COMPLETED TREATMENT
    * INMED PHARMACEUTICALS INC - INTERNATIONAL PATENT GRANTED
FOR USE
OF CANNABINOL FOR TREATMENT OF EPIDERMOLYSIS BULLOSA
    * INMED PHARMACEUTICALS INC - ADOLESCENT PATIENTS NOW
ELIGIBLE TO
PARTICIPATE IN CLINICAL TRIAL

Source text for Eikon:  ID:nGNX4sGrCJ 
Further company coverage:  INM.O 

 ((reuters.briefs@thomsonreuters.com;))